Chronic Viral Infection

Inflammation triggers unsustainable immune response

Scientists at the University of Basel discovered a fundamental new mechanism explaining the inadequate immune defense against chronic viral infection. These results may open up new avenues for vaccine development.

In the course of an infection or upon vaccination, specialized cells of our immune system, so-called B cells, produce antibodies that bind viruses and inactivate them. In the context of chronic viral infections such as HIV or hepatitis C virus, however, antibody production by B cells is quantitatively inadequate and starts too late.

A team of scientists headed by Prof. Daniel Pinschewer at the Department of Biomedicine, University of Basel, reports that the inadequate antibody response to chronic viral diseases is due to the strong inflammatory reaction upon infection. While most pronounced at the onset of an infection, inflammation can persist for decades, especially in HIV/AIDS.

Hasty immune response lasts only short-term

Under the influence of inflammatory messengers, so called interferons, B cells produce as many antibodies as they possibly can. Unfortunately, this hasty response occurs at the expense of sustainability. B cells that turn on antibody production too quickly lose their potential to proliferate and die shortly thereafter. As a consequence, the immune response takes an impetuous start but subsides rapidly.

The scientists assume that this panic reaction of B cells reflects a mechanism ensuring an optimized response to acute life threatening infections. In the context of chronic infections, however, the battle is not decided within a matter of days, but rather only after months or years. Under these circumstances, the hasty reaction of our body seems inappropriate and may actually favor the virus.

Cornerstone for new vaccines

For viral diseases such as HIV or hepatitis C protective vaccines remain unavailable. The scientists are hopeful that the discovery of this fundamental mechanism may provide a basis to improve vaccination strategies against chronic viral diseases.


Original article
Fallet et al.: Interferon-driven deletion of antiviral B cells at the onset of chronic infection; Sci. Immunol. 1, eaah6817 (2016) | doi: 10.1126/sciimmunol.aah6817

Source: University of Basel

24.10.2016

More on the subject:
Read all latest stories

Related articles

Photo

Sponsored • Disease management

Multiplex Testing: A Solution to Manage Surge in Respiratory Illnesses as Concerns over “Multi-demic” Rise

Eunsin Bae, M.D. specializes in laboratory medicine and leads the Institute of Clinical Research at Seegene Inc. Her research focuses on microbiology, molecular biology, and hematology. Dr. Bae is…

Photo

Sponsored • POCT

Pluslife Biotech – Mini Dock POC Molecular System

The Pluslife Mini Dock System is a Next-Generation POC molecular diagnostic tool that can be used in different application scenarios, which aims to help the decentralization of MDx in diagnosing…

Photo

Sponsored • Diagnostics Alliance against SARS-CoV-2

The Global Alliance for Diagnostics Sets Next-Generation POC Molecular Testing Collaboration

The coronavirus pandemic is a huge challenge for global public health and welfare. Decentralized, affordable POC MDx platforms would allow more effective control of SARS-CoV-2 and other infections.

Related products

Siemens Healthineers – Fast Track Real-time PCR assays

Infectious Disease

Siemens Healthineers – Fast Track Real-time PCR assays

Siemens Healthineers
Sarstedt - COVID-19 virus diagnostics products

Saliva Collection

Sarstedt - COVID-19 virus diagnostics products

SARSTEDT AG & CO. KG
Subscribe to Newsletter